AU2017384317C1 - PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF - Google Patents

PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF Download PDF

Info

Publication number
AU2017384317C1
AU2017384317C1 AU2017384317A AU2017384317A AU2017384317C1 AU 2017384317 C1 AU2017384317 C1 AU 2017384317C1 AU 2017384317 A AU2017384317 A AU 2017384317A AU 2017384317 A AU2017384317 A AU 2017384317A AU 2017384317 C1 AU2017384317 C1 AU 2017384317C1
Authority
AU
Australia
Prior art keywords
compound
formula
salt
chem
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017384317A
Other languages
English (en)
Other versions
AU2017384317B2 (en
AU2017384317A1 (en
Inventor
Jan BORNHOLDT
Soren Ebdrup
Akinobu HIGASHI
Takashi Inaba
Kim Lebek JENSEN
Anders Klarskov Petersen
Tsubasa TAKEICHI
Hiromu TAKIGUCHI
Per Vedsoe
Takashi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Japan Tobacco Inc
Original Assignee
Leo Pharma AS
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS, Japan Tobacco Inc filed Critical Leo Pharma AS
Publication of AU2017384317A1 publication Critical patent/AU2017384317A1/en
Publication of AU2017384317B2 publication Critical patent/AU2017384317B2/en
Priority to AU2022203506A priority Critical patent/AU2022203506B2/en
Application granted granted Critical
Publication of AU2017384317C1 publication Critical patent/AU2017384317C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2017384317A 2016-12-21 2017-12-20 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF Active AU2017384317C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022203506A AU2022203506B2 (en) 2016-12-21 2022-05-24 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-247607 2016-12-21
JP2016247607 2016-12-21
PCT/JP2017/045729 WO2018117152A1 (ja) 2016-12-21 2017-12-20 7H-ピロロ[2,3-d]ピリミジン誘導体の製造方法及びその合成中間体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203506A Division AU2022203506B2 (en) 2016-12-21 2022-05-24 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF

Publications (3)

Publication Number Publication Date
AU2017384317A1 AU2017384317A1 (en) 2019-07-11
AU2017384317B2 AU2017384317B2 (en) 2022-03-10
AU2017384317C1 true AU2017384317C1 (en) 2022-06-30

Family

ID=62627423

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017384317A Active AU2017384317C1 (en) 2016-12-21 2017-12-20 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF
AU2022203506A Active AU2022203506B2 (en) 2016-12-21 2022-05-24 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022203506A Active AU2022203506B2 (en) 2016-12-21 2022-05-24 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF

Country Status (14)

Country Link
US (3) US11673900B2 (enExample)
EP (2) EP4793278A2 (enExample)
JP (2) JP6434678B2 (enExample)
KR (1) KR102546513B1 (enExample)
CN (2) CN117865992A (enExample)
AU (2) AU2017384317C1 (enExample)
BR (1) BR112019012688A2 (enExample)
CA (1) CA3047891A1 (enExample)
ES (1) ES3068086T3 (enExample)
IL (2) IL288080B2 (enExample)
MX (2) MX2019007542A (enExample)
PL (1) PL3560932T3 (enExample)
TW (2) TWI816651B (enExample)
WO (1) WO2018117152A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017026173A2 (pt) 2015-07-07 2018-08-14 Japan Tobacco, Inc. Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo
PL3560932T3 (pl) 2016-12-21 2026-06-29 Japan Tobacco Inc. Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
JP2026509302A (ja) 2023-03-17 2026-03-17 レオ ファーマ アクティーゼルスカブ 中等症ないし重症の慢性手湿疹を有する患者における慢性手湿疹を処置する方法
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108731A1 (en) * 2003-05-30 2004-12-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
WO2011013785A1 (ja) * 2009-07-31 2011-02-03 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
US7230119B2 (en) 2004-08-25 2007-06-12 Biocryst Pharmaceuticals, Inc. Process for the preparation of substituted pyrrolidine derivatives and intermediates
WO2008036755A1 (en) 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
SG191291A1 (en) 2011-01-19 2013-07-31 Galapagos Nv Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
CN103570601B (zh) 2012-07-20 2016-03-30 重庆博腾制药科技股份有限公司 一种光学活性药物中间体的制备方法
HUE034210T2 (hu) 2013-03-05 2018-02-28 Theravance Biopharma R&D Ip Llc Neprilizininhibitorok
JP6500634B2 (ja) * 2015-06-24 2019-04-17 株式会社Ihi 溶接装置及び溶接方法
BR112017026173A2 (pt) * 2015-07-07 2018-08-14 Japan Tobacco, Inc. Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo
TWI822666B (zh) * 2016-12-21 2023-11-21 日商日本煙草產業股份有限公司 Janus激酶抑制劑之結晶型
PL3560932T3 (pl) 2016-12-21 2026-06-29 Japan Tobacco Inc. Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108731A1 (en) * 2003-05-30 2004-12-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
WO2011013785A1 (ja) * 2009-07-31 2011-02-03 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANKOWSKI, K. et al., European Journal of Medicinal Chemistry, 2013, 63, 457 - 467 *
NUNEZ-VILLANUEVA, D. et al., Journal of Organic Chemistry, 2011, 76(16), 6592 - 6603 *
VAN NISPEN, J. W. et al., International Journal of Peptide & Protein Research, (1977), 9(3), 193 - 202 *

Also Published As

Publication number Publication date
AU2017384317B2 (en) 2022-03-10
CA3047891A1 (en) 2018-06-28
JPWO2018117152A1 (ja) 2018-12-20
RU2019122691A3 (enExample) 2021-02-08
WO2018117152A1 (ja) 2018-06-28
EP3560932B1 (en) 2026-03-11
TWI816651B (zh) 2023-10-01
PL3560932T3 (pl) 2026-06-29
CN110300756B (zh) 2024-01-02
BR112019012688A2 (pt) 2019-11-19
IL267385B2 (en) 2023-06-01
US20200216470A1 (en) 2020-07-09
US20250084106A1 (en) 2025-03-13
IL288080B2 (en) 2024-03-01
CN110300756A (zh) 2019-10-01
KR102546513B1 (ko) 2023-06-23
JP6434678B2 (ja) 2018-12-05
US11673900B2 (en) 2023-06-13
RU2019122691A (ru) 2021-01-25
IL288080A (en) 2022-01-01
EP4793278A2 (en) 2026-08-19
ES3068086T3 (es) 2026-05-27
CN117865992A (zh) 2024-04-12
US12195481B2 (en) 2025-01-14
IL288080B1 (en) 2023-11-01
EP3560932A4 (en) 2020-10-28
MX2019007542A (es) 2019-11-18
IL267385A (enExample) 2019-07-31
JP7098496B2 (ja) 2022-07-11
TW202400613A (zh) 2024-01-01
JP2019048806A (ja) 2019-03-28
AU2022203506A1 (en) 2022-06-09
US20240140967A1 (en) 2024-05-02
AU2017384317A1 (en) 2019-07-11
IL267385B1 (enExample) 2023-02-01
AU2022203506B2 (en) 2024-02-08
EP3560932A1 (en) 2019-10-30
KR20190095408A (ko) 2019-08-14
TW201829422A (zh) 2018-08-16
TWI854815B (zh) 2024-09-01
EP3560932C0 (en) 2026-03-11
MX2024005335A (es) 2024-05-20

Similar Documents

Publication Publication Date Title
AU2022203506B2 (en) PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF
AU2016289061B2 (en) Method for producing 7H-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
EP3560931B1 (en) PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND CO-CRYSTALS THEREOF
RU2776802C2 (ru) Способ получения производных 7h-пирроло[2,3-d]пиримидина и промежуточных продуктов для их синтеза

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PROCESS FOR PREPARING 7H-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 MAR 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 17 MAR 2022

FGA Letters patent sealed or granted (standard patent)